# First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

> **NCT05607498** · PHASE1 · RECRUITING · sponsor: **EpimAb Biotherapeutics (Suzhou)Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced/Metastatic Solid Tumors
- Relapse/Refractory Lymphoma

## Interventions

- **DRUG:** EMB07

## Key facts

- **NCT ID:** NCT05607498
- **Lead sponsor:** EpimAb Biotherapeutics (Suzhou)Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607498, "First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05607498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*